Literature DB >> 33478015

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer.

Vincenza Conteduca1, Alessandra Mosca2, Nicole Brighi1, Ugo de Giorgi1, Pasquale Rescigno3.   

Abstract

Prostate cancer is one of the most frequent cancers in men and is a common cause of cancer-related death. Despite significant progress in the diagnosis and treatment of this tumor, patients who relapse after radical treatments inevitably develop metastatic disease. Patient stratification is therefore key in this type of cancer, and there is an urgent need for prognostic biomarkers that can define patients' risk of cancer-related death. In the last 10 years, multiple prognostic factors have been identified and studied. Here, we review the literature available and discuss the most common aberrant genomic pathways in metastatic castration-resistant prostate cancer shown to have a prognostic relevance in this setting.

Entities:  

Keywords:  DNA repair defects; PTEN; androgen receptor; prognostic biomarkers; prostate cancer

Year:  2021        PMID： 33478015      PMCID： PMC7835961          DOI： 10.3390/cells10010193

Source DB:  PubMed          Journal:  Cells        ISSN： 2073-4409            Impact factor:   6.600


  91 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory.

Authors:  Melina Arnold; Henrike E Karim-Kos; Jan Willem Coebergh; Graham Byrnes; Ahti Antilla; Jacques Ferlay; Andrew G Renehan; David Forman; Isabelle Soerjomataram
Journal:  Eur J Cancer       Date:  2013-10-08       Impact factor: 9.162

3.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

4.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Authors:  James D Joseph; Nhin Lu; Jing Qian; John Sensintaffar; Gang Shao; Dan Brigham; Michael Moon; Edna Chow Maneval; Isan Chen; Beatrice Darimont; Jeffrey H Hager
Journal:  Cancer Discov       Date:  2013-06-18       Impact factor: 39.397

5.  Plasma AR and abiraterone-resistant prostate cancer.

Authors:  Alessandro Romanel; Delila Gasi Tandefelt; Vincenza Conteduca; Anuradha Jayaram; Nicola Casiraghi; Daniel Wetterskog; Samanta Salvi; Dino Amadori; Zafeiris Zafeiriou; Pasquale Rescigno; Diletta Bianchini; Giorgia Gurioli; Valentina Casadio; Suzanne Carreira; Jane Goodall; Anna Wingate; Roberta Ferraldeschi; Nina Tunariu; Penny Flohr; Ugo De Giorgi; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2015-11-04       Impact factor: 17.956

6.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

7.  Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Authors:  Xiaotun Zhang; Colm Morrissey; Shihua Sun; Melanie Ketchandji; Peter S Nelson; Lawrence D True; Funda Vakar-Lopez; Robert L Vessella; Stephen R Plymate
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

8.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.

Authors:  Akash Kumar; Ilsa Coleman; Colm Morrissey; Xiaotun Zhang; Lawrence D True; Roman Gulati; Ruth Etzioni; Hamid Bolouri; Bruce Montgomery; Thomas White; Jared M Lucas; Lisha G Brown; Ruth F Dumpit; Navonil DeSarkar; Celestia Higano; Evan Y Yu; Roger Coleman; Nikolaus Schultz; Min Fang; Paul H Lange; Jay Shendure; Robert L Vessella; Peter S Nelson
Journal:  Nat Med       Date:  2016-02-29       Impact factor: 53.440

9.  Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.

Authors:  Pasquale Rescigno; David Lorente; David Dolling; Roberta Ferraldeschi; Daniel Nava Rodrigues; Ruth Riisnaes; Susana Miranda; Diletta Bianchini; Zafeiris Zafeiriou; Spyridon Sideris; Ana Ferreira; Ines Figueiredo; Semini Sumanasuriya; Joaquin Mateo; Raquel Perez-Lopez; Adam Sharp; Nina Tunariu; Johann S de Bono
Journal:  Eur Urol Oncol       Date:  2018-05

10.  Genomic correlates of clinical outcome in advanced prostate cancer.

Authors:  Wassim Abida; Joanna Cyrta; Glenn Heller; Davide Prandi; Joshua Armenia; Ilsa Coleman; Marcin Cieslik; Matteo Benelli; Dan Robinson; Eliezer M Van Allen; Andrea Sboner; Tarcisio Fedrizzi; Juan Miguel Mosquera; Brian D Robinson; Navonil De Sarkar; Lakshmi P Kunju; Scott Tomlins; Yi Mi Wu; Daniel Nava Rodrigues; Massimo Loda; Anuradha Gopalan; Victor E Reuter; Colin C Pritchard; Joaquin Mateo; Diletta Bianchini; Susana Miranda; Suzanne Carreira; Pasquale Rescigno; Julie Filipenko; Jacob Vinson; Robert B Montgomery; Himisha Beltran; Elisabeth I Heath; Howard I Scher; Philip W Kantoff; Mary-Ellen Taplin; Nikolaus Schultz; Johann S deBono; Francesca Demichelis; Peter S Nelson; Mark A Rubin; Arul M Chinnaiyan; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-06       Impact factor: 11.205
View more
  3 in total

1.  Isolation and Characterization of Urinary Extracellular Vesicles from Healthy Donors and Patients with Castration-Resistant Prostate Cancer.

Authors:  Haneul Lee; Su Jin Kang; Jimin Lee; Kyong Hwa Park; Won Jong Rhee
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

2.  Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.

Authors:  Vincenza Conteduca; Emanuela Scarpi; Paola Caroli; Cristian Lolli; Giorgia Gurioli; Nicole Brighi; Giulia Poti; Alberto Farolfi; Amelia Altavilla; Giuseppe Schepisi; Federica Matteucci; Giovanni Paganelli; Ugo De Giorgi
Journal:  Mol Oncol       Date:  2021-11-09       Impact factor: 6.603

Review 3.  Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer.

Authors:  Fabrizio Fontana; Patrizia Limonta
Journal:  Cells       Date:  2021-05-07       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.